Statistics for A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Total visits

views
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study 264

Total visits per month

views
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0
May 2025 0

File Visits

views
nihms734272.pdf 409
java.util.UUID:b2c46861-e2a7-4a29-b75c-06e9f3b0feeb 78
java.util.UUID:c62e2869-34b1-48d0-9588-b763f177a3b3 10
java.util.UUID:a7ad6a35-c467-4822-872b-a5dfe26c9f82 4

Top country views

views
United States 192
Germany 17
Sweden 9
Ukraine 8
Russia 6
China 4
United Kingdom 3
Canada 2
Poland 2
France 1
India 1
Italy 1
Malaysia 1
Philippines 1

Top city views

views
Wilmington 48
Fairfield 32
Ann Arbor 24
Kiez 15
Houston 12
Cambridge 9
White Plains 9
Stockholm 8
Jacksonville 7
Kiev 7
Beijing 3
Saint Petersburg 3
Gunzenhausen 2
Henryk 2
Moscow 2
San Francisco 2
Toronto 2
Washington 2
Abingdon 1
Baltimore 1
Brooklyn 1
Grùmolo 1
Indiana 1
Motala 1
Paris 1
Philadelphia 1
Scottsdale 1
Seremban 1